Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: A systematic review and meta-analysis

Journal of Viral Hepatitis

Volumn 21, Issue 3, 2014, Pages 163-170

  Lee, D H ^a   Lee, Jeong Hoon ^a   Kim, Y J ^a   Park, N H ^b   Cho, Y ^a   Lee, Y B ^a   Yoo, J J ^a   Lee, M ^a   Cho, Y Y ^a   Choi, W M ^a   Yu, S J ^a   Yoon, J H ^a   Kim, C Y ^a   Lee, H S ^a  

^a Seoul National University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

hepatitis B surface antigen; hepatitis B virus; interleukin 28B; meta analysis; polymorphism

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 28B;

ARTICLE; CHRONIC HEPATITIS; ETHNICITY; GENETIC HETEROGENEITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; PLASMA CLEARANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; INTERLEUKIN 28B; META-ANALYSIS; POLYMORPHISM;

HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; ODDS RATIO; POLYMORPHISM, GENETIC; PUBLICATION BIAS;

EID: 84892823295     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12193     Document Type: Article

References (32)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP,. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125.
2. McMahon BJ, Holck P, Bulkow L, Snowball M,. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135 (9): 759-768.
3. Yu MW, Chang HC, Liaw YF, et al,. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92 (14): 1159-1164.
4. Shen FM, Lee MK, Gong HM, Cai XQ, King MC,. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet 1991; 49 (1): 88-93.
5. Shin HD, Park BL, Cheong HS, Yoon JH, Kim YJ, Lee HS,. SPP1 polymorphisms associated with HBV clearance and HCC occurrence. Int J Epidemiol 2007; 36 (5): 1001-1008.
6. Jung YJ, Kim YJ, Kim LH, et al,. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology 2007; 50 (5): 369-376.
7. Kim YJ, Kim HY, Kim JS, et al,. Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Viral Hepatitis 2010; 17 (7): 518-526.
8. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
9. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
10. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.
11. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR,. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80 (9): 4501-4509.
12. Ank N, West H, Paludan SR,. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006; 26 (6): 373-379.
13. Sonneveld MJ, Wong VW, Woltman AM, et al,. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142 (3): 513-520 e1.
14. Lampertico P, Vigano M, Cheroni C, et al,. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57 (3): 890-896.
15. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
16. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al,. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52 (1): 33-37.
17. Kim SU, Song KJ, Chang HY, et al,. Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. PLoS ONE 2013; 8 (7): e69166.
18. Seto WK, Wong DK, Kopaniszen M, et al,. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56 (12): 1695-1703.
19. Lee DH, Cho Y, Seo JY, et al,. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology 2013; 56 (2): 84-90.
20. Dunford L, Carr MJ, Dean J, et al,. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS ONE 2012; 7 (6): e39027.
21. Ren S, Lu J, Du X, et al,. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother 2012; 61 (9): 1433-1439.
22. Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY,. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 2012; 79 (4): 302-305.
23. Li W, Jiang Y, Jin Q, et al,. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011; 31 (8): 1118-1126.
24. Hwa Park N, Jae Kim C,. IL28B polymorphisms are not associated with outcomes of hepatitis B virus infection. Hepatology 2011; 54: 1094A.
25. Martin-Carbonero L, Rallon NI, Benito JM, Poveda E, Gonzalez-Lahoz J, Soriano V,. Short communication: does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? AIDS Res Hum Retroviruses 2012; 28 (10): 1262-1264.
26. Martin MP, Qi Y, Goedert JJ, et al,. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202 (11): 1749-1753.
27. Yapali S, Cetintas A, Salman E, et al,. IL28B genotype has no impact on spontaneous Hepatitis B surface antigen (HBSAG) clearance in inactive carriers: a long term, case-matched retrospective cohort study. J Hepatol 2012; 56: S193.
28. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6 (7): e1000100.
29. Stang A,. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25 (9): 603-605.
30. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139 (2): 499-509.
31. Urban TJ, Thompson AJ, Bradrick SS, et al,. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52 (6): 1888-1896.
32. Marcello T, Grakoui A, Barba-Spaeth G, et al,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131 (6): 1887-1898.